MX2018001324A - Crystalline form of lorlatinib free base. - Google Patents
Crystalline form of lorlatinib free base.Info
- Publication number
- MX2018001324A MX2018001324A MX2018001324A MX2018001324A MX2018001324A MX 2018001324 A MX2018001324 A MX 2018001324A MX 2018001324 A MX2018001324 A MX 2018001324A MX 2018001324 A MX2018001324 A MX 2018001324A MX 2018001324 A MX2018001324 A MX 2018001324A
- Authority
- MX
- Mexico
- Prior art keywords
- free base
- crystalline form
- lorlatinib free
- lorlatinib
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl- 5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4, 3-h][2,5,11]benzoxadiazacyclo- tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199418P | 2015-07-31 | 2015-07-31 | |
| US201662352349P | 2016-06-20 | 2016-06-20 | |
| PCT/IB2016/054483 WO2017021823A1 (en) | 2015-07-31 | 2016-07-27 | Crystalline form of lorlatinib free base |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018001324A true MX2018001324A (en) | 2018-04-30 |
Family
ID=56686850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001324A MX2018001324A (en) | 2015-07-31 | 2016-07-27 | Crystalline form of lorlatinib free base. |
| MX2021002220A MX2021002220A (en) | 2015-07-31 | 2016-07-27 | Crystalline form of lorlatinib free base. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002220A MX2021002220A (en) | 2015-07-31 | 2016-07-27 | Crystalline form of lorlatinib free base. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10420749B2 (en) |
| EP (2) | EP3328867B9 (en) |
| JP (1) | JP6218253B2 (en) |
| KR (1) | KR102088188B1 (en) |
| CN (3) | CN116063322A (en) |
| AU (1) | AU2016304420B2 (en) |
| BR (1) | BR112017028604A2 (en) |
| CA (1) | CA2937257C (en) |
| CY (1) | CY1123689T1 (en) |
| DK (2) | DK3798222T3 (en) |
| ES (1) | ES2842302T3 (en) |
| FI (1) | FI3798222T3 (en) |
| HK (1) | HK1252845A1 (en) |
| HU (1) | HUE052790T2 (en) |
| MX (2) | MX2018001324A (en) |
| PL (2) | PL3328867T3 (en) |
| PT (2) | PT3798222T (en) |
| RU (1) | RU2018101363A (en) |
| SG (1) | SG10201913200XA (en) |
| SI (2) | SI3328867T1 (en) |
| TW (1) | TWI616449B (en) |
| WO (1) | WO2017021823A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017049383A1 (en) | 2015-09-24 | 2017-03-30 | Cyclenium Pharma Inc. | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same |
| US11078215B2 (en) | 2016-04-08 | 2021-08-03 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| WO2018232506A1 (en) * | 2017-06-22 | 2018-12-27 | Cyclenium Pharma Inc. | Libraries of pyridine-containing macrocyclic compounds and methods of making and using the same |
| ES2952985T3 (en) * | 2017-10-10 | 2023-11-07 | Pfizer | Crystalline form of lorlatinib free base hydrate |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| EP3784675A1 (en) | 2018-04-23 | 2021-03-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| CN109232607A (en) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | Laura replaces the synthetic method of Buddhist nun |
| CA3126788A1 (en) * | 2019-01-17 | 2020-07-23 | Pfizer Inc. | Crystalline form of a cdk inhibitor |
| WO2021011345A1 (en) * | 2019-07-18 | 2021-01-21 | Pliva Hrvatska D.O.O | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN110483551B (en) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | Crystals of Laratinib free base |
| CN110530998A (en) * | 2019-09-16 | 2019-12-03 | 山东省药学科学院 | A kind of Laura is for Buddhist nun and containing Laura for the detection method in relation to substance in the preparation of Buddhist nun |
| EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
| CN112824417A (en) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | Preparation method of Laolatinib |
| WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| ES2621220T3 (en) * | 2012-03-06 | 2017-07-03 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP3013835B1 (en) * | 2013-06-28 | 2017-12-13 | Pfizer Inc | Solid forms of a macrocyclic kinase inhibitor |
| CN104513253A (en) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | Macrocyclic compounds for the treatment of proliferative diseases |
| US11078215B2 (en) | 2016-04-08 | 2021-08-03 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| ES2952985T3 (en) | 2017-10-10 | 2023-11-07 | Pfizer | Crystalline form of lorlatinib free base hydrate |
-
2016
- 2016-07-27 SI SI201631027T patent/SI3328867T1/en unknown
- 2016-07-27 JP JP2016146928A patent/JP6218253B2/en active Active
- 2016-07-27 AU AU2016304420A patent/AU2016304420B2/en active Active
- 2016-07-27 RU RU2018101363A patent/RU2018101363A/en unknown
- 2016-07-27 HU HUE16751665A patent/HUE052790T2/en unknown
- 2016-07-27 CA CA2937257A patent/CA2937257C/en active Active
- 2016-07-27 BR BR112017028604A patent/BR112017028604A2/en not_active Application Discontinuation
- 2016-07-27 TW TW105123769A patent/TWI616449B/en active
- 2016-07-27 PL PL16751665T patent/PL3328867T3/en unknown
- 2016-07-27 PT PT202023362T patent/PT3798222T/en unknown
- 2016-07-27 EP EP16751665.7A patent/EP3328867B9/en active Active
- 2016-07-27 PT PT167516657T patent/PT3328867T/en unknown
- 2016-07-27 SG SG10201913200XA patent/SG10201913200XA/en unknown
- 2016-07-27 MX MX2018001324A patent/MX2018001324A/en unknown
- 2016-07-27 SI SI201631780T patent/SI3798222T1/en unknown
- 2016-07-27 CN CN202310197825.6A patent/CN116063322A/en active Pending
- 2016-07-27 MX MX2021002220A patent/MX2021002220A/en unknown
- 2016-07-27 FI FIEP20202336.2T patent/FI3798222T3/en active
- 2016-07-27 PL PL20202336.2T patent/PL3798222T3/en unknown
- 2016-07-27 WO PCT/IB2016/054483 patent/WO2017021823A1/en active Application Filing
- 2016-07-27 US US15/743,894 patent/US10420749B2/en active Active
- 2016-07-27 ES ES16751665T patent/ES2842302T3/en active Active
- 2016-07-27 KR KR1020187002904A patent/KR102088188B1/en active IP Right Grant
- 2016-07-27 CN CN201680042321.5A patent/CN107849060A/en active Pending
- 2016-07-27 DK DK20202336.2T patent/DK3798222T3/en active
- 2016-07-27 DK DK16751665.7T patent/DK3328867T3/en active
- 2016-07-27 CN CN202310214099.4A patent/CN116063323A/en active Pending
- 2016-07-27 EP EP20202336.2A patent/EP3798222B1/en active Active
-
2018
- 2018-09-21 HK HK18112176.1A patent/HK1252845A1/en unknown
-
2019
- 2019-08-08 US US16/535,747 patent/US11020376B2/en active Active
-
2020
- 2020-12-30 CY CY20201101227T patent/CY1123689T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018001324A (en) | Crystalline form of lorlatinib free base. | |
| ZA202001661B (en) | Crystalline form of lorlatinib free base hydrate | |
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| PH12017500367A1 (en) | Compounds that inhibit mcl-1 protein | |
| MX2015011898A (en) | Pyrazolo compounds and uses thereof. | |
| MD20170016A2 (en) | Aminopyrimidinyl compounds as JAK inhibitors | |
| MX2015012414A (en) | Salt of omecamtiv mecarbil and process for preparing salt. | |
| WO2017059385A8 (en) | 11,13-modified saxitoxins for the treatment of pain | |
| MX2015012502A (en) | Dna-pk inhibitors. | |
| MY193728A (en) | Muscarinic receptor agonists | |
| MY192216A (en) | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| TW201613864A (en) | Novel compounds | |
| GEP201706760B (en) | Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| AU2015316010A8 (en) | Crystalline forms of 6-( (6, 7-dimethoxyquinazolin-4-yl) oxy) -N,2-dimethylbenzofuran-3-carboxamide | |
| MX2015000179A (en) | Itraconazole compositions and dosage forms, and methods of using the same. | |
| PH12016501997A1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
| MX2021008225A (en) | Compositions and methods for treatment of abnormal cell growth. | |
| MX2018005134A (en) | Fviii formulation. | |
| IN2013MU03469A (en) |